계산생물학 시장 : 제품 유형, 기술, 용도, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Computational Biology Market is projected to grow by USD 30.78 billion at a CAGR of 19.52% by 2032.

Computational Biology Executive Summary

Computational biology has moved from a specialist research discipline to a strategic engine for genomics, drug discovery, precision medicine, agricultural biotechnology, and public health surveillance. The field combines bioinformatics, systems biology, molecular modeling, machine learning, high-performance computing, and multi-omics analytics to interpret biological data at scale.

Industry adoption is being accelerated by validated public assets such as the Protein Data Bank, NCBI resources, EMBL-EBI databases, UK Biobank, the NIH All of Us Research Program, and the AlphaFold Protein Structure Database, which has made more than 200 million predicted protein structures available to researchers. These data foundations are reshaping how organizations identify disease mechanisms, prioritize therapeutic targets, and design evidence-based biological products.

Transformative Shifts in the Computational Biology Landscape

The computational biology landscape is being transformed by the convergence of population-scale sequencing, cloud-native bioinformatics, automated laboratories, and interoperable health data. Declining sequencing costs, broader access to next-generation sequencing, and growth in single-cell and spatial omics are expanding the volume and complexity of biological datasets.

At the same time, research organizations are shifting from isolated analysis pipelines to integrated platforms that connect genomics, transcriptomics, proteomics, metabolomics, imaging, clinical phenotypes, and real-world evidence. This shift favors providers that can deliver reproducible workflows, secure data governance, scalable compute, and domain-specific analytics for regulated life science environments.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact across computational biology by improving pattern recognition, protein structure prediction, target discovery, biomarker identification, and clinical trial stratification. Deep learning models now help analyze high-dimensional omics data, predict molecular interactions, support de novo protein design, and reduce the search space in early-stage drug discovery.

The value of AI depends on validated datasets, transparent model performance, bias monitoring, and biological confirmation. Industry leaders are therefore combining foundation models, graph neural networks, molecular simulations, and wet-lab validation rather than treating AI outputs as standalone evidence. This integration is strengthening decision quality while raising demand for explainable AI, data lineage, and regulatory-grade documentation.

Key Regional Insights

Asia-Pacific is becoming a high-growth center for computational biology as China, India, Japan, South Korea, Australia, and Singapore expand genomics programs, AI research capacity, and biomanufacturing infrastructure. North America remains the deepest innovation base, supported by NIH-funded research, large biobanks, advanced cloud platforms, FDA engagement with real-world evidence, and a dense biotechnology ecosystem. Europe continues to lead in cross-border research coordination through EMBL-EBI, ELIXIR, Horizon Europe, national genome programs, and strict data protection frameworks.

Latin America is gaining momentum through infectious disease genomics, biodiversity research, cancer studies, and academic bioinformatics networks, with Brazil and Mexico playing important roles. The Middle East is investing in precision medicine and national genome initiatives, particularly in the Gulf, while Africa is building capacity through pathogen surveillance, human genetics research, and collaborative networks such as H3Africa and regional sequencing centers. Together, these regions show that computational biology adoption is increasingly global, but infrastructure, workforce depth, and data governance maturity vary significantly.

Key Group Insights

ASEAN countries are expanding computational biology through biomedical research hubs, digital health programs, and regional infectious disease surveillance, with Singapore acting as a major genomics and AI anchor. The GCC is advancing population genomics and precision health through national strategies, hospital modernization, and sovereign cloud investments. The European Union is strengthening data-sharing frameworks through the European Health Data Space, the 1+ Million Genomes initiative, ELIXIR, and research funding that supports FAIR data principles.

BRICS economies are important because they combine large populations, biodiversity, sequencing demand, and growing domestic bioinformatics capabilities. The G7 continues to dominate advanced computational biology through research funding, pharmaceutical R&D, supercomputing, and regulatory science. NATO countries add relevance through biosecurity, pathogen surveillance, and dual-use risk governance, making trusted computational biology infrastructure an increasingly important component of national resilience.

Key Country Insights

The United States leads in computational biology due to NIH funding, top-tier academic centers, large-scale programs such as All of Us, and a strong AI-drug discovery ecosystem. Canada benefits from genomics networks, public health data science, and cancer research collaborations, while Mexico and Brazil are strengthening regional capacity through university-led bioinformatics, pathogen sequencing, and biodiversity-linked genomics. In Europe, the United Kingdom stands out through Genomics England and the NHS Genomic Medicine Service, while Germany, France, Italy, and Spain combine strong academic research, pharmaceutical capabilities, and EU-funded data infrastructure; Russia retains scientific expertise but faces constraints related to international collaboration and advanced computing access.

China is a major force in sequencing, AI research, and biomanufacturing, supported by large institutions and extensive genomic infrastructure. India is scaling genomics through initiatives such as GenomeIndia, digital public infrastructure, and a large biotechnology talent pool. Japan combines AMED-backed biomedical research, supercomputing strength, and aging-population health priorities, while Australia has built a strong precision medicine and population genomics profile. South Korea is advancing bioinformatics, digital hospitals, and AI-enabled drug discovery through coordinated national biotechnology strategies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize interoperable computational biology platforms that connect multi-omics, clinical, imaging, and real-world data while maintaining strong privacy, cybersecurity, and auditability. Investment in standardized workflows, containerized pipelines, metadata quality, and FAIR data practices can improve reproducibility and reduce the friction that slows translation from discovery to clinical or commercial application.

Executives should also build AI governance models that require biological validation, model monitoring, and clear accountability. Strategic partnerships with academic centers, sequencing laboratories, hospitals, and regulatory experts can accelerate innovation while reducing execution risk. Workforce development in bioinformatics, machine learning, statistics, and molecular biology should be treated as a core growth requirement rather than a support function.

Research Methodology

This executive summary is based on a structured research methodology that combines secondary research, expert interpretation, and cross-validation of public evidence. Sources considered include peer-reviewed literature, public research databases, clinical trial registries, government funding programs, regulatory guidance, patent activity, scientific infrastructure initiatives, and internationally recognized genomics and bioinformatics resources.

Insights were assessed for relevance to computational biology adoption, AI integration, regional competitiveness, and enterprise strategy. Findings were triangulated across data availability, institutional capacity, technology readiness, regulatory context, and demonstrated use cases in genomics, drug discovery, precision medicine, public health, and biotechnology innovation.

Conclusion

Computational biology is becoming a core capability for organizations seeking faster discovery, better biological understanding, and more precise decision-making. The combination of AI, multi-omics, cloud computing, and validated biological databases is enabling new approaches to target identification, therapeutic development, diagnostics, and health system innovation.

The next phase of competition will be defined by trustworthy data ecosystems, explainable models, reproducible workflows, and the ability to translate computational insight into experimentally validated outcomes. Organizations that align scientific rigor with scalable digital infrastructure will be best positioned to capture long-term value in computational biology.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Computational Biology Market, by Product Type

• 7.1. Instruments
  • 7.1.1. Imaging Systems
  • 7.1.2. Mass Spectrometry Instruments
  • 7.1.3. Microarray Scanners
  • 7.1.4. PCR Instruments
  • 7.1.5. Sequencing Instruments
• 7.2. Reagents & Consumables
• 7.3. Software & Services
  • 7.3.1. Bioinformatics Services
  • 7.3.2. Data Analysis Software
  • 7.3.3. Instrument Maintenance Services

8. Computational Biology Market, by Technology

• 8.1. Imaging Systems
  • 8.1.1. Confocal Microscopy
  • 8.1.2. Electron Microscopy
  • 8.1.3. Fluorescence Imaging
• 8.2. Microarray
  • 8.2.1. DNA Microarray
  • 8.2.2. Protein Microarray
• 8.3. Mass Spectrometry
• 8.4. Next Gen Sequencing
  • 8.4.1. Illumina Sequencing
  • 8.4.2. Ion Torrent Sequencing

9. Computational Biology Market, by Application

• 9.1. Diagnostics
  • 9.1.1. Cancer Diagnostics
  • 9.1.2. Genetic Testing
  • 9.1.3. Infectious Disease
• 9.2. Drug Discovery
  • 9.2.1. Lead Optimization
  • 9.2.2. Target Identification
  • 9.2.3. Toxicity Screening
• 9.3. Genomic Analysis
  • 9.3.1. DNA Sequencing
  • 9.3.2. Epigenetic Analysis
  • 9.3.3. RNA Sequencing
• 9.4. Proteomic Analysis
  • 9.4.1. Protein Identification
  • 9.4.2. PTM Analysis
  • 9.4.3. Quantitative Proteomics

10. Computational Biology Market, by End User

• 10.1. Academic & Research Institutes
  • 10.1.1. Government Research Centers
  • 10.1.2. Universities
• 10.2. Contract Research Organizations
  • 10.2.1. Large CROs
  • 10.2.2. Niche CROs
• 10.3. Hospitals & Diagnostic Laboratories
  • 10.3.1. Hospital Laboratories
  • 10.3.2. Independent Diagnostic Laboratories
• 10.4. Pharmaceutical & Biotechnology Companies
  • 10.4.1. Biotechnology Companies
  • 10.4.2. Pharmaceutical Companies

11. Computational Biology Market, by Distribution Channel

• 11.1. Online
• 11.2. Offline

12. Computational Biology Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Computational Biology Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Computational Biology Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. 10x Genomics, Inc.
• 16.2. Agilent Technologies, Inc.
• 16.3. BGI Group
• 16.4. Bio-Rad Laboratories, Inc.
• 16.5. BioDiscovery Group
• 16.6. biomodal Limited
• 16.7. DNASTAR, Inc.
• 16.8. Eurofins Genomics LLC
• 16.9. F. Hoffmann-La Roche Ltd
• 16.10. Genevia Technologies Oy
• 16.11. Genomics Ltd.
• 16.12. HaploX
• 16.13. Illumina, Inc.
• 16.14. Integrated DNA Technologies, Inc.
• 16.15. Labcorp Genetics Inc.
• 16.16. Labvantage - Biomax GmbH
• 16.17. Novo Nordisk A/S
• 16.18. Oxford Nanopore Technologies plc.
• 16.19. Pacific Biosciences of California, Inc.
• 16.20. Partek Incorporated
• 16.21. PerkinElmer, Inc.
• 16.22. Qiagen N.V.
• 16.23. RIKEN GENESIS CO.,LTD.
• 16.24. SOPHiA GENETICS SA
• 16.25. Telesis Bio Inc.
• 16.26. Thermo Fisher Scientific Inc.
• 16.27. Veracyte, Inc.
• 16.28. Waters Corporation